Press releaseBusiness Wire
TriSalus Life Sciences
TLSI · NASDAQ
$3.66+$0.13 (+3.68%)TodayMarket closed ·
Prev close $3.53
Latest news
- News
Full Transcript: TriSalus Life Sciences Q2 2026 Earnings Call
- NewsAvi Kapoor
Crude Oil Gains 1%; Cintas Earnings Top Views
- NewsVandana Singh
TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support
- News
Market-Moving News for September 23rd
- Press releaseBusiness Wire
TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization
- Press releaseBusiness Wire
TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
- Press releaseBusiness Wire
TriSalus Life Sciences Reports Second Quarter 2026 Results
- Press releaseBusiness Wire
TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
- Press releaseBusiness Wire
TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
- Press releaseBusiness Wire
TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
- Press releaseGlobe Newswire
TLSI INVESTOR ALERT: Holzer & Holzer, LLC Investigation of TriSalus Life Sciences, Inc.
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
- Press releaseBusiness Wire
TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
- Press releasePRNewswire
TLSI (TLSI) Securities Fraud Investigation - Levi & Korsinsky
- Press releaseBusiness Wire
Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
- Press releaseBusiness Wire
TriSalus Life Sciences Inc. (TLSI) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
- Press releaseBusiness Wire
TLSI Investor Alert: Levi & Korsinsky Investigates TLSI (TLSI) for Potential Securities Fraud
- Press releaseBusiness Wire
Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
- NewsAvi Kapoor
Nasdaq Surges Over 1%; Alibaba Shares Gain After Q4 Results
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsAvi Kapoor
Dow Falls 200 Points; US Producer Prices Surge In April
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- News
TriSalus Life Sciences Q1 2026 Earnings Call: Complete Transcript
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- Press releaseBusiness Wire
TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth
- Press releaseBusiness Wire
Real-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge Avoidance
- Press releaseBusiness Wire
TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors
- Press releaseBusiness Wire
TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting
- Press releaseBusiness Wire
TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer
- Press releaseBusiness Wire
TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models
- Press releaseBusiness Wire
TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance
- Press releaseBusiness Wire
TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance
- Press releaseBusiness Wire
TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance
- Press releaseBusiness Wire
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure
- Press releaseBusiness Wire
TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance
- Press releaseBusiness Wire
TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results
- Press releaseBusiness Wire
TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.